Overview
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Eligibility
Inclusion Criteria:
- All participants who are treated with lecanemab in routine clinical practice
Exclusion Criteria:
- None